You are about to leave jnjmedtech.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.
Intervene early to delay disease progression
Early AF ablation can mean patients are less likely to develop persistent AF, leading to successful results over time.1
Optimize your treatment approach
When patients need more than PVI, Biosense Webster technology allows for a patient-tailored approach.2
Deliver lasting impact
Our technology and workfows help you achieve long-term outcomes that keep your patients living their best lives possible.2†
References
* In a prospective, multicenter, randomized, controlled 2-arm study (ATTEST, n=255). Cox model with multiple baseline covariates and treatment as the time-dependent covariate determined hazard ratio:
0.107 (95% CI: 0.024–0.47; P=0.0031).
† Long-term outcomes of clinical success rate of 80% at 15 months.
1. Kuck K-H, Lebedev DS, Mikhaylov EN, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: The randomized controlled Atrial Fibrillation Progression Trial (ATTEST).
Europace. 2021;23(3):362-369.
2. Mansour M, Calkins H, Osorio J et al. Persistent atrial fibrillation ablation with contact force sensing catheter: The prospective multicenter PRECEPT Trial. JACC Clin Electrophysiol. 2020;6(8):958-969.
The THERMOCOOL SMARTTOUCH® SF Catheter is indicated for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation (AF) and for drug refractory recurrent symptomatic persistent AF (continuous AF > 7 days but < 1 year), refractory or intolerant to at least 1 Class I or III AAD, when used with the CARTO® 3 System.
173700-210413 ©Biosense Webster, Inc. 2021 Last Updated on 4/13/2021.